The Experts below are selected from a list of 73893 Experts worldwide ranked by ideXlab platform
Eliezer K Ngoran - One of the best experts on this subject based on the ideXlab platform.
-
efficacy and safety of single 40 mg kg oral praziquantel in the treatment of schistosomiasis in Preschool Age versus school Age children an individual participant data meta analysis
PLOS Neglected Tropical Diseases, 2020Co-Authors: Piero Olliaro, Jean T Coulibaly, Amadou Garba, Christine Halleux, Jennifer Keiser, Charles H King, Francisca Mutapi, Eliezer K NgoranAbstract:Background Better knowledge of the efficacy and safety of single 40 mg/kg oral praziquantel in Preschool-Age children is required, should preventive chemotherapy programs for schistosomiasis be expanded to include this Age group. Methodology We analyzed individual participant-level data from 16 studies (13 single-arm or cohort studies and three randomized trials), amounting to 683 Preschool-Age children (Aged <6 years) and 2,010 school-Age children (Aged 6–14 years). Children had a documented Schistosoma mansoni or S. haematobium infection, were treated with single 40 mg/kg oral praziquantel, and assessed between 21 and 60 days post-treatment. Efficacy was expressed as arithmetic mean and individual egg reduction rate (ERR) and meta-analyzed using general linear models and mixed models. Safety was summarized using reported adverse events (AEs). Principal findings Preschool-Age children had significantly lower baseline Schistosoma egg counts and more losses to follow-up compared to school-Age children. No difference in efficacy was found between Preschool- and school-Age children using a general linear model of individual-participant ERR with baseline log-transformed egg count as covariate and study, Age, and sex as fixed variables, and a mixed model with a random effect on the study. Safety was reported in only four studies (n = 1,128 individuals); few AEs were reported in Preschool-Age children 4 and 24 hours post-treatment as well as at follow-up. Three severe but not serious AEs were recorded in school-Age children during follow-up. Conclusions/Significance There is no indication that single 40 mg/kg oral praziquantel would be less efficacious and safe in Preschool-Age children compared to school-Age children, with the caveat that only few randomized comparisons exist between the two Age groups. Preventive chemotherapy might therefore be extended to Preschool-Age children, with proper monitoring of its efficacy and safety.
-
efficacy and safety of single dose 40 mg kg oral praziquantel in the treatment of schistosomiasis in Preschool Age versus school Age children an individual participant data meta analysis
PLOS Neglected Tropical Diseases, 2020Co-Authors: Piero Olliaro, Jean T Coulibaly, Amadou Garba, Christine Halleux, Jennifer Keiser, Charles H King, Francisca Mutapi, Eliezer K NgoranAbstract:Background Better knowledge of the efficacy and safety of single-dose 40 mg/kg oral praziquantel in Preschool-Age children is required, should preventive chemotherapy programs for schistosomiasis be expanded to include this Age group. Methodology We analyzed individual participant-level data from 16 studies (13 single-arm or cohort studies and three randomized trials), amounting to 683 Preschool-Age children (Aged <6 years) and 2,010 school-Age children (Aged 6–14 years). Children had a documented Schistosoma mansoni or S. haematobium infection, were treated with single 40 mg/kg oral praziquantel, and assessed between 21 and 60 days post-treatment. Efficacy was expressed as arithmetic mean and individual egg reduction rate (ERR) and meta-analyzed using general linear models and mixed models. Safety was summarized using reported adverse events (AEs). Principal findings Preschool-Age children had significantly lower baseline Schistosoma egg counts and more losses to follow-up compared to school-Age children. No difference in efficacy was found between Preschool- and school-Age children using a general linear model of individual-participant ERR with baseline log-transformed egg count as covariate and study, Age, and sex as fixed variables, and a mixed model with a random effect on the study. Safety was reported in only four studies (n = 1,128 individuals); few AEs were reported in Preschool-Age children 4 and 24 hours post-treatment as well as at follow-up. Three severe but not serious AEs were recorded in school-Age children during follow-up. Conclusions/significance There is no indication that single-dose 40 mg/kg oral praziquantel would be less efficacious and less safe in Preschool-Age children compared to school-Age children, with the caveat that only few randomized comparisons exist between the two Age groups. Preventive chemotherapy might therefore be extended to Preschool-Age children, with proper monitoring of its efficacy and safety.
Charles H King - One of the best experts on this subject based on the ideXlab platform.
-
efficacy and safety of single 40 mg kg oral praziquantel in the treatment of schistosomiasis in Preschool Age versus school Age children an individual participant data meta analysis
PLOS Neglected Tropical Diseases, 2020Co-Authors: Piero Olliaro, Jean T Coulibaly, Amadou Garba, Christine Halleux, Jennifer Keiser, Charles H King, Francisca Mutapi, Eliezer K NgoranAbstract:Background Better knowledge of the efficacy and safety of single 40 mg/kg oral praziquantel in Preschool-Age children is required, should preventive chemotherapy programs for schistosomiasis be expanded to include this Age group. Methodology We analyzed individual participant-level data from 16 studies (13 single-arm or cohort studies and three randomized trials), amounting to 683 Preschool-Age children (Aged <6 years) and 2,010 school-Age children (Aged 6–14 years). Children had a documented Schistosoma mansoni or S. haematobium infection, were treated with single 40 mg/kg oral praziquantel, and assessed between 21 and 60 days post-treatment. Efficacy was expressed as arithmetic mean and individual egg reduction rate (ERR) and meta-analyzed using general linear models and mixed models. Safety was summarized using reported adverse events (AEs). Principal findings Preschool-Age children had significantly lower baseline Schistosoma egg counts and more losses to follow-up compared to school-Age children. No difference in efficacy was found between Preschool- and school-Age children using a general linear model of individual-participant ERR with baseline log-transformed egg count as covariate and study, Age, and sex as fixed variables, and a mixed model with a random effect on the study. Safety was reported in only four studies (n = 1,128 individuals); few AEs were reported in Preschool-Age children 4 and 24 hours post-treatment as well as at follow-up. Three severe but not serious AEs were recorded in school-Age children during follow-up. Conclusions/Significance There is no indication that single 40 mg/kg oral praziquantel would be less efficacious and safe in Preschool-Age children compared to school-Age children, with the caveat that only few randomized comparisons exist between the two Age groups. Preventive chemotherapy might therefore be extended to Preschool-Age children, with proper monitoring of its efficacy and safety.
-
efficacy and safety of single dose 40 mg kg oral praziquantel in the treatment of schistosomiasis in Preschool Age versus school Age children an individual participant data meta analysis
PLOS Neglected Tropical Diseases, 2020Co-Authors: Piero Olliaro, Jean T Coulibaly, Amadou Garba, Christine Halleux, Jennifer Keiser, Charles H King, Francisca Mutapi, Eliezer K NgoranAbstract:Background Better knowledge of the efficacy and safety of single-dose 40 mg/kg oral praziquantel in Preschool-Age children is required, should preventive chemotherapy programs for schistosomiasis be expanded to include this Age group. Methodology We analyzed individual participant-level data from 16 studies (13 single-arm or cohort studies and three randomized trials), amounting to 683 Preschool-Age children (Aged <6 years) and 2,010 school-Age children (Aged 6–14 years). Children had a documented Schistosoma mansoni or S. haematobium infection, were treated with single 40 mg/kg oral praziquantel, and assessed between 21 and 60 days post-treatment. Efficacy was expressed as arithmetic mean and individual egg reduction rate (ERR) and meta-analyzed using general linear models and mixed models. Safety was summarized using reported adverse events (AEs). Principal findings Preschool-Age children had significantly lower baseline Schistosoma egg counts and more losses to follow-up compared to school-Age children. No difference in efficacy was found between Preschool- and school-Age children using a general linear model of individual-participant ERR with baseline log-transformed egg count as covariate and study, Age, and sex as fixed variables, and a mixed model with a random effect on the study. Safety was reported in only four studies (n = 1,128 individuals); few AEs were reported in Preschool-Age children 4 and 24 hours post-treatment as well as at follow-up. Three severe but not serious AEs were recorded in school-Age children during follow-up. Conclusions/significance There is no indication that single-dose 40 mg/kg oral praziquantel would be less efficacious and less safe in Preschool-Age children compared to school-Age children, with the caveat that only few randomized comparisons exist between the two Age groups. Preventive chemotherapy might therefore be extended to Preschool-Age children, with proper monitoring of its efficacy and safety.
Jennifer Keiser - One of the best experts on this subject based on the ideXlab platform.
-
efficacy and safety of single 40 mg kg oral praziquantel in the treatment of schistosomiasis in Preschool Age versus school Age children an individual participant data meta analysis
PLOS Neglected Tropical Diseases, 2020Co-Authors: Piero Olliaro, Jean T Coulibaly, Amadou Garba, Christine Halleux, Jennifer Keiser, Charles H King, Francisca Mutapi, Eliezer K NgoranAbstract:Background Better knowledge of the efficacy and safety of single 40 mg/kg oral praziquantel in Preschool-Age children is required, should preventive chemotherapy programs for schistosomiasis be expanded to include this Age group. Methodology We analyzed individual participant-level data from 16 studies (13 single-arm or cohort studies and three randomized trials), amounting to 683 Preschool-Age children (Aged <6 years) and 2,010 school-Age children (Aged 6–14 years). Children had a documented Schistosoma mansoni or S. haematobium infection, were treated with single 40 mg/kg oral praziquantel, and assessed between 21 and 60 days post-treatment. Efficacy was expressed as arithmetic mean and individual egg reduction rate (ERR) and meta-analyzed using general linear models and mixed models. Safety was summarized using reported adverse events (AEs). Principal findings Preschool-Age children had significantly lower baseline Schistosoma egg counts and more losses to follow-up compared to school-Age children. No difference in efficacy was found between Preschool- and school-Age children using a general linear model of individual-participant ERR with baseline log-transformed egg count as covariate and study, Age, and sex as fixed variables, and a mixed model with a random effect on the study. Safety was reported in only four studies (n = 1,128 individuals); few AEs were reported in Preschool-Age children 4 and 24 hours post-treatment as well as at follow-up. Three severe but not serious AEs were recorded in school-Age children during follow-up. Conclusions/Significance There is no indication that single 40 mg/kg oral praziquantel would be less efficacious and safe in Preschool-Age children compared to school-Age children, with the caveat that only few randomized comparisons exist between the two Age groups. Preventive chemotherapy might therefore be extended to Preschool-Age children, with proper monitoring of its efficacy and safety.
-
efficacy and safety of single dose 40 mg kg oral praziquantel in the treatment of schistosomiasis in Preschool Age versus school Age children an individual participant data meta analysis
PLOS Neglected Tropical Diseases, 2020Co-Authors: Piero Olliaro, Jean T Coulibaly, Amadou Garba, Christine Halleux, Jennifer Keiser, Charles H King, Francisca Mutapi, Eliezer K NgoranAbstract:Background Better knowledge of the efficacy and safety of single-dose 40 mg/kg oral praziquantel in Preschool-Age children is required, should preventive chemotherapy programs for schistosomiasis be expanded to include this Age group. Methodology We analyzed individual participant-level data from 16 studies (13 single-arm or cohort studies and three randomized trials), amounting to 683 Preschool-Age children (Aged <6 years) and 2,010 school-Age children (Aged 6–14 years). Children had a documented Schistosoma mansoni or S. haematobium infection, were treated with single 40 mg/kg oral praziquantel, and assessed between 21 and 60 days post-treatment. Efficacy was expressed as arithmetic mean and individual egg reduction rate (ERR) and meta-analyzed using general linear models and mixed models. Safety was summarized using reported adverse events (AEs). Principal findings Preschool-Age children had significantly lower baseline Schistosoma egg counts and more losses to follow-up compared to school-Age children. No difference in efficacy was found between Preschool- and school-Age children using a general linear model of individual-participant ERR with baseline log-transformed egg count as covariate and study, Age, and sex as fixed variables, and a mixed model with a random effect on the study. Safety was reported in only four studies (n = 1,128 individuals); few AEs were reported in Preschool-Age children 4 and 24 hours post-treatment as well as at follow-up. Three severe but not serious AEs were recorded in school-Age children during follow-up. Conclusions/significance There is no indication that single-dose 40 mg/kg oral praziquantel would be less efficacious and less safe in Preschool-Age children compared to school-Age children, with the caveat that only few randomized comparisons exist between the two Age groups. Preventive chemotherapy might therefore be extended to Preschool-Age children, with proper monitoring of its efficacy and safety.
Piero Olliaro - One of the best experts on this subject based on the ideXlab platform.
-
efficacy and safety of single 40 mg kg oral praziquantel in the treatment of schistosomiasis in Preschool Age versus school Age children an individual participant data meta analysis
PLOS Neglected Tropical Diseases, 2020Co-Authors: Piero Olliaro, Jean T Coulibaly, Amadou Garba, Christine Halleux, Jennifer Keiser, Charles H King, Francisca Mutapi, Eliezer K NgoranAbstract:Background Better knowledge of the efficacy and safety of single 40 mg/kg oral praziquantel in Preschool-Age children is required, should preventive chemotherapy programs for schistosomiasis be expanded to include this Age group. Methodology We analyzed individual participant-level data from 16 studies (13 single-arm or cohort studies and three randomized trials), amounting to 683 Preschool-Age children (Aged <6 years) and 2,010 school-Age children (Aged 6–14 years). Children had a documented Schistosoma mansoni or S. haematobium infection, were treated with single 40 mg/kg oral praziquantel, and assessed between 21 and 60 days post-treatment. Efficacy was expressed as arithmetic mean and individual egg reduction rate (ERR) and meta-analyzed using general linear models and mixed models. Safety was summarized using reported adverse events (AEs). Principal findings Preschool-Age children had significantly lower baseline Schistosoma egg counts and more losses to follow-up compared to school-Age children. No difference in efficacy was found between Preschool- and school-Age children using a general linear model of individual-participant ERR with baseline log-transformed egg count as covariate and study, Age, and sex as fixed variables, and a mixed model with a random effect on the study. Safety was reported in only four studies (n = 1,128 individuals); few AEs were reported in Preschool-Age children 4 and 24 hours post-treatment as well as at follow-up. Three severe but not serious AEs were recorded in school-Age children during follow-up. Conclusions/Significance There is no indication that single 40 mg/kg oral praziquantel would be less efficacious and safe in Preschool-Age children compared to school-Age children, with the caveat that only few randomized comparisons exist between the two Age groups. Preventive chemotherapy might therefore be extended to Preschool-Age children, with proper monitoring of its efficacy and safety.
-
efficacy and safety of single dose 40 mg kg oral praziquantel in the treatment of schistosomiasis in Preschool Age versus school Age children an individual participant data meta analysis
PLOS Neglected Tropical Diseases, 2020Co-Authors: Piero Olliaro, Jean T Coulibaly, Amadou Garba, Christine Halleux, Jennifer Keiser, Charles H King, Francisca Mutapi, Eliezer K NgoranAbstract:Background Better knowledge of the efficacy and safety of single-dose 40 mg/kg oral praziquantel in Preschool-Age children is required, should preventive chemotherapy programs for schistosomiasis be expanded to include this Age group. Methodology We analyzed individual participant-level data from 16 studies (13 single-arm or cohort studies and three randomized trials), amounting to 683 Preschool-Age children (Aged <6 years) and 2,010 school-Age children (Aged 6–14 years). Children had a documented Schistosoma mansoni or S. haematobium infection, were treated with single 40 mg/kg oral praziquantel, and assessed between 21 and 60 days post-treatment. Efficacy was expressed as arithmetic mean and individual egg reduction rate (ERR) and meta-analyzed using general linear models and mixed models. Safety was summarized using reported adverse events (AEs). Principal findings Preschool-Age children had significantly lower baseline Schistosoma egg counts and more losses to follow-up compared to school-Age children. No difference in efficacy was found between Preschool- and school-Age children using a general linear model of individual-participant ERR with baseline log-transformed egg count as covariate and study, Age, and sex as fixed variables, and a mixed model with a random effect on the study. Safety was reported in only four studies (n = 1,128 individuals); few AEs were reported in Preschool-Age children 4 and 24 hours post-treatment as well as at follow-up. Three severe but not serious AEs were recorded in school-Age children during follow-up. Conclusions/significance There is no indication that single-dose 40 mg/kg oral praziquantel would be less efficacious and less safe in Preschool-Age children compared to school-Age children, with the caveat that only few randomized comparisons exist between the two Age groups. Preventive chemotherapy might therefore be extended to Preschool-Age children, with proper monitoring of its efficacy and safety.
Francisca Mutapi - One of the best experts on this subject based on the ideXlab platform.
-
efficacy and safety of single 40 mg kg oral praziquantel in the treatment of schistosomiasis in Preschool Age versus school Age children an individual participant data meta analysis
PLOS Neglected Tropical Diseases, 2020Co-Authors: Piero Olliaro, Jean T Coulibaly, Amadou Garba, Christine Halleux, Jennifer Keiser, Charles H King, Francisca Mutapi, Eliezer K NgoranAbstract:Background Better knowledge of the efficacy and safety of single 40 mg/kg oral praziquantel in Preschool-Age children is required, should preventive chemotherapy programs for schistosomiasis be expanded to include this Age group. Methodology We analyzed individual participant-level data from 16 studies (13 single-arm or cohort studies and three randomized trials), amounting to 683 Preschool-Age children (Aged <6 years) and 2,010 school-Age children (Aged 6–14 years). Children had a documented Schistosoma mansoni or S. haematobium infection, were treated with single 40 mg/kg oral praziquantel, and assessed between 21 and 60 days post-treatment. Efficacy was expressed as arithmetic mean and individual egg reduction rate (ERR) and meta-analyzed using general linear models and mixed models. Safety was summarized using reported adverse events (AEs). Principal findings Preschool-Age children had significantly lower baseline Schistosoma egg counts and more losses to follow-up compared to school-Age children. No difference in efficacy was found between Preschool- and school-Age children using a general linear model of individual-participant ERR with baseline log-transformed egg count as covariate and study, Age, and sex as fixed variables, and a mixed model with a random effect on the study. Safety was reported in only four studies (n = 1,128 individuals); few AEs were reported in Preschool-Age children 4 and 24 hours post-treatment as well as at follow-up. Three severe but not serious AEs were recorded in school-Age children during follow-up. Conclusions/Significance There is no indication that single 40 mg/kg oral praziquantel would be less efficacious and safe in Preschool-Age children compared to school-Age children, with the caveat that only few randomized comparisons exist between the two Age groups. Preventive chemotherapy might therefore be extended to Preschool-Age children, with proper monitoring of its efficacy and safety.
-
efficacy and safety of single dose 40 mg kg oral praziquantel in the treatment of schistosomiasis in Preschool Age versus school Age children an individual participant data meta analysis
PLOS Neglected Tropical Diseases, 2020Co-Authors: Piero Olliaro, Jean T Coulibaly, Amadou Garba, Christine Halleux, Jennifer Keiser, Charles H King, Francisca Mutapi, Eliezer K NgoranAbstract:Background Better knowledge of the efficacy and safety of single-dose 40 mg/kg oral praziquantel in Preschool-Age children is required, should preventive chemotherapy programs for schistosomiasis be expanded to include this Age group. Methodology We analyzed individual participant-level data from 16 studies (13 single-arm or cohort studies and three randomized trials), amounting to 683 Preschool-Age children (Aged <6 years) and 2,010 school-Age children (Aged 6–14 years). Children had a documented Schistosoma mansoni or S. haematobium infection, were treated with single 40 mg/kg oral praziquantel, and assessed between 21 and 60 days post-treatment. Efficacy was expressed as arithmetic mean and individual egg reduction rate (ERR) and meta-analyzed using general linear models and mixed models. Safety was summarized using reported adverse events (AEs). Principal findings Preschool-Age children had significantly lower baseline Schistosoma egg counts and more losses to follow-up compared to school-Age children. No difference in efficacy was found between Preschool- and school-Age children using a general linear model of individual-participant ERR with baseline log-transformed egg count as covariate and study, Age, and sex as fixed variables, and a mixed model with a random effect on the study. Safety was reported in only four studies (n = 1,128 individuals); few AEs were reported in Preschool-Age children 4 and 24 hours post-treatment as well as at follow-up. Three severe but not serious AEs were recorded in school-Age children during follow-up. Conclusions/significance There is no indication that single-dose 40 mg/kg oral praziquantel would be less efficacious and less safe in Preschool-Age children compared to school-Age children, with the caveat that only few randomized comparisons exist between the two Age groups. Preventive chemotherapy might therefore be extended to Preschool-Age children, with proper monitoring of its efficacy and safety.
